Atropine eye drops to reduce pain and posterior synechiae after vitrectomy
Official title: APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes
Run by University of California, San Francisco · NCT07434635 · Data updated 2026-11-12
We will test whether atropine 1% eye drops used after vitrectomy surgery reduce pain and lower the chance of posterior synechiae.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 62 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | March 10, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2029 |
| Registry record updated | July 31, 2026 |
| Trial ID | NCT07434635 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients undergoing vitrectomy who can give informed consent and are not using postoperative topical NSAIDs or altered anti-inflammatory regimens and who are not allergic to atropine.
✕Probably not a fit
Patients who are prescribed postoperative topical nonsteroidal anti-inflammatory drugs, require altered anti-inflammatory schedules, or have an atropine allergy are excluded and may not receive benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional study compares postoperative outcomes in patients undergoing vitrectomy who receive atropine 1% eye drops versus those who do not. Eligible participants must be able to give informed consent and cannot be on postoperative topical nonsteroidal anti-inflammatory drugs or have an altered anti-inflammatory drop schedule; patients with a documented atropine allergy are excluded. Investigators will monitor postoperative pain, the development of posterior synechiae, and routine recovery measures following surgery. The study is conducted at the University of California, San Francisco and follows patients through the standard postoperative period.
Why it matters
Potential benefit: If successful, atropine could reduce postoperative pain and lower the incidence of posterior synechiae, improving recovery after vitrectomy.
How similar studies have gone: Atropine is commonly used after eye surgery but high-quality comparative data are limited, so this trial adds to mixed existing evidence on its benefits.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient undergoing vitrectomy surgery * able to give informed consent Exclusion Criteria: * post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications * subjects with altered post-operative eyedrop schedule for enhanced inflammation control * documented allergy to atropine
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Jay Stewart, MD — University of California, San Francisco
- Study coordinator: Jay Stewart, MD
- Email: eyestudy@ucsf.edu
- Phone: 415-353-9635
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day eye health orientation for Female Community Health Volunteers to boost visits to a local vision center
This project will try a one-day eye health orientation for Female Community Health Volunteers to see if it increases the number of patients coming to a nearby vision center.
-
Sepofarsen injections for LCA10 due to the CEP290 p.Cys998X mutation
This study will test whether sepofarsen eye injections can improve vision in children and adults with LCA10 caused by the CEP290 c.2991+1655A>G (p.Cys998X) mutation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.